HOME >> MEDICINE >> NEWS
Acrux and Oreganon further expand their collaboration

Drug delivery company Acrux (ASX: ACR), announced today that it has signed a further agreement with Organon, the human healthcare business unit of Akzo Nobel, expanding the two parties' collaboration. This follows the recently announced deal under which Organon and Acrux will develop and commercialise contraceptives, delivered through the skin using Acrux's unique spray technology.

Under the new agreement, Organon has licensed Acrux's technology for delivery of a non-hormone, proprietary Organon drug, for a substantial global women's health market.

"The expansion of our important relationship with Organon, one of the leading innovators in women's health, confirms that our unique spray technology has even broader potential" said Acrux CEO Richard Treagus.

"This adds a new, non-hormone drug to our pipeline and demonstrates the potential to use the technology to deliver drugs owned by our partners", he added.

Organon executive vice president, Research and Development, David Nicholson commented "The Acrux technology is an appealing method of delivering medication, with the potential to extend the choices available for women to fit their needs and lifestyle."

Acrux will be responsible for developing formulations of the undisclosed compound and upon successful completion; Organon will undertake and fund all clinical trials, regulatory submissions, manufacturing and commercialization efforts.

Acrux may receive payments totalling US$12 million as development and regulatory milestones are achieved.

Acrux will also earn royalties on worldwide sales of the product.


'"/>

Contact: Richard Treagus
richard.treagus@acrux.com.au
61-383-790-100
Research Australia
6-Mar-2007


Page: 1

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. Acrux granted first grant in Europe, triggering payment from Lilly
3. Acrux patent portfolio advances in USA
4. Acrux acquires rights to commercialise worlds first contraceptive spray
5. Four new us patents granted to Acrux for transdermal drug delivery
6. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
7. Stomach cancer rate set to fall further 25 percent over next decade
8. High tech help to prevent further heart disease
9. Altered activity in receptor pair points to further complexity in schizophrenia pathology
10. Mount Sinai and YAI/NIPD Network join forces to further quality of care for people with autism
11. Data further examines Seroquel (quetiapine fumarate) treatment for bipolar depression

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Acrux and Oreganon further expand their collaboration

(Date:8/2/2015)... ... 2015 , ... Molecular biologists in New South Wales say a protein linked ... just posted an article on the new research. Click here to read it ... expression in tissue samples from 42 patients with peritoneal mesothelioma and found a direct ...
(Date:8/1/2015)... ... 02, 2015 , ... Back packs can be dangerous? Whaaat?! , Not the ... wreck havoc on a kid's spine. With school starting again, most kids will be ... sure you are aware of how to help them prevent injuries by understanding backpack ...
(Date:8/1/2015)... CA (PRWEB) , ... August 01, 2015 , ... Have you ever wondered what “Karma” ... when you hear the word “Karma.” , Vedic tradition, which gave birth to Hinduism, ... is one of the central concepts of this tradition. According to the wisdom of this ...
(Date:8/1/2015)... ... , ... Calvary Hospital today announced that it is embarking on a yearlong ... to bring this Torah – dating from 1880 – back to kosher status, so ... , Scroll No. 515, from the town of Taus-Domazlice, is on permanent loan to ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of ... unification of their Healthy Home mission with the HOPE Movement of EvolvHealth. In what ... of both companies have agreed to join their missions of purpose together to change ...
Breaking Medicine News(10 mins):Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 Edwards ... the science of heart valves and hemodynamic monitoring, today announced ... company,s Board of Directors. "Bob is an ardent ... been a true privilege to have him on Edwards, board ... A. Mussallem , Edwards, chairman and CEO.  "Bob has provided ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
Cached News: